All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

What constitutes refractory disease in the context of WM?

On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on: What constitutes refractory disease in the context of Waldenstrom's Macroglobulinemia (WM)? This discussion also featured Christian Buske, Monique Minnema, Sheeba Koshy Thomas, and Jorge J. Castillo.

What constitutes refractory disease in the context of WM?

The panel begins by discussing disease manifestations and measurable parameters prior to, and posttreatment as well as the challenges of refractory disease not being clearly defined. Castillo mentions the contradictions of those patients who display symptom improvements but show no actual response in IgM levels, and vice versa, as this challenges the diagnosis of refractory disease. Sheeba highlights that patients on fixed-duration therapies who display progressive shortening of response duration until new symptoms appear/symptom reoccurrence could be added into the refractory disease group. Minnema highlights the value of defining an achievement goal for each patient, particularly for M-protein related diseases where numbers may be more important than clinical presentation. Lastly, Buske emphasizes the importance of not defining patients with refractory disease too early, as improvements are commonly expected after ending treatment; assessing patients in a case-by-case scenario is imperative.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox